Inhibrx Biosciences has opened enrollment for new Ewing sarcoma and colorectal adenocarcinoma cohorts in its ongoing Phase 1/2 trial of Ozekibart. The expansion

Inhibrx Biosciences has opened enrollment for new Ewing sarcoma and colorectal adenocarcinoma cohorts in its ongoing Phase 1/2 trial of Ozekibart. The expansion broadens safety and efficacy testing as the company targets hard-to-treat cancers.